Viatris Reveals Generic Rybelsus Candidate As Part Of Continued Complex Push

Eight Complex Programs Are At Various Stages Of Development

10 Mar 2021

Recently-formed Viatris is looking to build on the success of several high-margin complex generics launches, including versions of Advair and Copaxone, by developing further candidates, including rivals to Novo Nordisk’s Rybelsus (semaglutide) and Victoza (liraglutide).

female hand arranging wood block stacking as step stair. Business concept growth success process — Viatris has numerous complex candidates pending approval, in development and as future targets. • Source: Shutterstock

Viatris Inc. has revealed as part of its complex generics pipeline a version of Novo Nordisk’s Rybelsus (semaglutide), introduced last year by the originator as the world’s first once-daily GLP-1 oral formulation for type 2 diabetes. However, the firm is keeping a lid on further complex pipeline projects that lack currently a “very definitive development timeline.”

Recent endeavors in the space have led Viatris to be a market leader “in value, volume and in total prescriptions”...